Rim Hasan1, Belal Firwana1, Tarig Elraiyah2, Juan Pablo Domecq3, Gabriela Prutsky3, Mohammed Nabhan2, Larry J Prokop4, Peter Henke5, Apostolos Tsapas6, Victor M Montori7, Mohammad Hassan Murad8. 1. Evidence-based Practice Center, Mayo Clinic, Rochester, Minn; Department of Internal Medicine, University of Missouri, Columbia, Mo. 2. Evidence-based Practice Center, Mayo Clinic, Rochester, Minn. 3. Evidence-based Practice Center, Mayo Clinic, Rochester, Minn; Unidad de Conocimiento y Evidencia (CONEVID), Lima, Peru. 4. Mayo Clinic Libraries, Mayo Clinic, Rochester, Minn. 5. Department of Surgery, University of Michigan Medical School, Ann Arbor, Mich. 6. Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece. 7. Evidence-based Practice Center, Mayo Clinic, Rochester, Minn; Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minn. 8. Evidence-based Practice Center, Mayo Clinic, Rochester, Minn; Division of Preventive, Occupational and Aerospace Medicine, Mayo Clinic, Rochester, Minn. Electronic address: murad.mohammad@mayo.edu.
Abstract
OBJECTIVE: The objective of this review was to synthesize the available randomized controlled trials (RCTs) estimating the relative efficacy and safety of intensive vs less intensive glycemic control in preventing diabetic foot syndrome. METHODS: We used the umbrella design (systematic review of systematic reviews) to identify eligible RCTs. Two reviewers determined RCT eligibility and extracted descriptive, methodologic, and diabetic foot outcome data. Random-effects meta-analysis was used to pool outcome data across studies, and the I(2) statistic was used to quantify heterogeneity. RESULTS: Nine RCTs enrolling 10,897 patients with type 2 diabetes were included and deemed to be at moderate risk of bias. Compared with less intensive glycemic control, intensive control (hemoglobin A1c, 6%-7.5%) was associated with a significant decrease in risk of amputation (relative risk [RR], 0.65; 95% confidence interval [CI], 0.45-0.94; I(2) = 0%). Intensive control was significantly associated with slower decline in sensory vibration threshold (mean difference, -8.27; 95% CI, -9.75 to -6.79). There was no effect on other neuropathic changes (RR, 0.89; 95% CI, 0.75-1.05; I(2) = 32%) or ischemic changes (RR, 0.92; 95% CI, 0.67-1.26; I(2) = 0%). The quality of evidence is likely moderate. CONCLUSIONS: Compared with less intensive glycemic control therapy, intensive control may decrease the risk of amputation in patients with diabetic foot syndrome. The reported risk reduction is likely overestimated because the trials were open and the decision to proceed with amputation could be influenced by glycemic control.
OBJECTIVE: The objective of this review was to synthesize the available randomized controlled trials (RCTs) estimating the relative efficacy and safety of intensive vs less intensive glycemic control in preventing diabetic foot syndrome. METHODS: We used the umbrella design (systematic review of systematic reviews) to identify eligible RCTs. Two reviewers determined RCT eligibility and extracted descriptive, methodologic, and diabetic foot outcome data. Random-effects meta-analysis was used to pool outcome data across studies, and the I(2) statistic was used to quantify heterogeneity. RESULTS: Nine RCTs enrolling 10,897 patients with type 2 diabetes were included and deemed to be at moderate risk of bias. Compared with less intensive glycemic control, intensive control (hemoglobin A1c, 6%-7.5%) was associated with a significant decrease in risk of amputation (relative risk [RR], 0.65; 95% confidence interval [CI], 0.45-0.94; I(2) = 0%). Intensive control was significantly associated with slower decline in sensory vibration threshold (mean difference, -8.27; 95% CI, -9.75 to -6.79). There was no effect on other neuropathic changes (RR, 0.89; 95% CI, 0.75-1.05; I(2) = 32%) or ischemic changes (RR, 0.92; 95% CI, 0.67-1.26; I(2) = 0%). The quality of evidence is likely moderate. CONCLUSIONS: Compared with less intensive glycemic control therapy, intensive control may decrease the risk of amputation in patients with diabetic foot syndrome. The reported risk reduction is likely overestimated because the trials were open and the decision to proceed with amputation could be influenced by glycemic control.
Authors: Kyrstin L Lane; Mohammed S Abusamaan; Betiel Fesseha Voss; Emilia G Thurber; Noora Al-Hajri; Shraddha Gopakumar; Jimmy T Le; Sharoon Gill; Jaime Blanck; Laura Prichett; Caitlin W Hicks; Ronald L Sherman; Christopher J Abularrage; Nestoras N Mathioudakis Journal: J Diabetes Complications Date: 2020-05-22 Impact factor: 2.852
Authors: Shipra Arya; Zachary O Binney; Anjali Khakharia; Chandler A Long; Luke P Brewster; Peter W Wilson; William D Jordan; Yazan Duwayri Journal: J Vasc Surg Date: 2017-08-31 Impact factor: 4.268
Authors: Maria Teresa B Abola; Jonathan Golledge; Tetsuro Miyata; Seung-Woon Rha; Bryan P Yan; Timothy C Dy; Marie Simonette V Ganzon; Pankaj Kumar Handa; Salim Harris; Jiang Zhisheng; Ramakrishna Pinjala; Peter Ashley Robless; Hiroyoshi Yokoi; Elaine B Alajar; April Ann Bermudez-Delos Santos; Elmer Jasper B Llanes; Gay Marjorie Obrado-Nabablit; Noemi S Pestaño; Felix Eduardo Punzalan; Bernadette Tumanan-Mendoza Journal: J Atheroscler Thromb Date: 2020-07-04 Impact factor: 4.928
Authors: Betiel K Fesseha; Christopher J Abularrage; Kathryn F Hines; Ronald Sherman; Priscilla Frost; Susan Langan; Joseph Canner; Kendall C Likes; Sayed M Hosseini; Gwendolyne Jack; Caitlin W Hicks; Swaytha Yalamanchi; Nestoras Mathioudakis Journal: Diabetes Care Date: 2018-04-16 Impact factor: 19.112
Authors: Robert L Ferrer; Carolina Gonzalez Schlenker; Inez Cruz; Polly Hitchcock Noël; Raymond F Palmer; Ramin Poursani; Carlos Roberto Jaén Journal: Ann Fam Med Date: 2022 Sep-Oct Impact factor: 5.707
Authors: João Soares Felício; Franciane Trindade Cunha de Melo; Giovana Miranda Vieira; Vitória Teixeira de Aquino; Fernanda de Souza Parente; Wanderson Maia da Silva; Nivin Mazen Said; Emanuele Rocha da Silva; Ana Carolina Contente Braga de Souza; Maria Clara Neres Iunes de Oliveira; Gabriela Nascimento de Lemos; Ícaro José Araújo de Souza; Angélica Leite de Alcântara; Lorena Vilhena de Moraes; João Felício Abrahão Neto; Natércia Neves Marques de Queiroz; Neyla Arroyo Lara Mourão; Pedro Paulo Freire Piani; Melissa de Sá Oliveira Dos Reis; Karem Mileo Felício Journal: BMC Cardiovasc Disord Date: 2022-06-27 Impact factor: 2.174
Authors: Ketan Dhatariya; Stephen C Bain; John B Buse; Richard Simpson; Lise Tarnow; Margit Staum Kaltoft; Michael Stellfeld; Karen Tornøe; Richard E Pratley Journal: Diabetes Care Date: 2018-08-02 Impact factor: 19.112